Search Results

JenaValve Trilogy Heart Valve System Launched in Europe

October 18, 2021—JenaValve Technology, Inc., a developer and manufacturer of transcatheter aortic valve replacement (TAVR) systems, announced the launch of the Trilogy heart valve system in Europe.

JenaValve’s Trilogy TAVI System Receives CE Mark Approval

May 25, 2021—JenaValve Technology, Inc. announced that it has received CE Mark approval for its transfemoral Trilogy transcatheter aortic valve implantation (TAVI) system for the treatment of severe, symptomatic aortic regurgitation (AR) and aortic stenosis (AS) in patients at high surgical risk.

Enrollment Begins in CE Mark Study for JenaValve's Next-Generation TAVR System to Treat Severe Aortic Regurgitation

June 25, 2018—JenaValve Technology, Inc. announced initiation of patient enrollment in the CE Mark study of its next-generation JenaValve pericardial transcatheter aortic valve replacement (TAVR) system using the Coronatix transfemoral delivery catheter for the percutaneous treatment of patients with symptomatic, severe aortic regurgitation (AR).

ESC/EACTS Valvular Heart Disease Guidelines Address TAVR for Aortic Regurgitation

September 12, 2025—Updated guidelines on valvular heart disease have been published by the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).

TEER Evaluated in MATTERHORN, RESHAPE-HF2, and Tri.fr Trials

September 16, 2024—The European Society of Cardiology (ESC) announced the presentation of three studies evaluating transcatheter edge-to-edge repair (TEER): MATTERHORN, RESHAPE-HF2, and Tri.fr.